# Cardiff Oncology, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Cardiff Oncology, Inc.).

## Overview

Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing onvansertib, an oral and highly selective PLK1 inhibitor, for cancer indications with high unmet medical need. The company’s core approach is to combine onvansertib with standard-of-care therapies and use biomarker-driven patient selection to improve response rates. Its lead development efforts are centered on RAS-mutated metastatic colorectal cancer, with additional investigator-initiated studies in pancreatic cancer, small cell lung cancer, triple negative breast cancer, and CMML. Cardiff Oncology is still pre-commercial and depends on clinical progress, regulatory success, and external financing to advance its pipeline.

## Products & services

• Onvansertib oral PLK1 inhibitor
• Combination oncology clinical development programs
• Biomarker-guided patient selection assays
• Investigator-initiated clinical trials
• Intellectual property licensing royalties

- **Lead drug candidate** (0%) — Onvansertib, an oral small-molecule PLK1 inhibitor being developed for multiple cancers.
- **Clinical development programs** (0%) — Combination trials pairing onvansertib with standard-of-care therapies in selected tumor types.
- **Biomarker and genomics-enabled development** (0%) — Tumor genomics and biomarker assays used to refine patient selection and response assessment.
- **Royalty income** (100%) — Sales-based or usage-based royalties from other intellectual property licenses unrelated to onvansertib.

- Onvansertib oral PLK1 inhibitor
- Combination oncology clinical development programs
- Biomarker-guided patient selection assays
- Investigator-initiated clinical trials
- Intellectual property licensing royalties

## Customers

Cardiff Oncology does not sell an approved commercial drug today, so its direct economic counterparties are primarily clinical trial sites, investigators, contract manufacturers, and licensing partners rather than end-patient customers. The company’s future commercial customers would be oncologists and healthcare systems treating patients with RAS-mutated mCRC and other difficult-to-treat cancers, if onvansertib is approved. In the current stage, the company also receives small royalty payments from licensees of other intellectual property, which are unrelated to its oncology pipeline. Because the business is still in development, success depends on trial enrollment, investigator support, and eventual physician adoption rather than traditional product sales.

- **Clinical trial investigators and sites** (primary) — Academic and community oncology centers enroll patients, run protocols, and generate the clinical data needed to advance onvansertib.
- **Patients with high-unmet-need cancers** (primary) — Patients with RAS-mutated metastatic colorectal cancer and other advanced cancers participate in trials because standard options are limited.
- **Oncology prescribers and treatment centers** (secondary) — If approved, oncologists and cancer centers would use onvansertib in combination regimens for biomarker-selected patients.
- **Intellectual property licensees** (secondary) — Third parties using licensed IP generate small royalty revenue unrelated to the lead oncology program.

- Clinical investigators and trial sites running onvansertib studies
- Cancer patients enrolled in mCRC, mPDAC, SCLC, mTNBC, and CMML trials
- Oncologists who would prescribe onvansertib if approved
- Hospitals and cancer centers that would administer combination regimens
- IP licensees generating sales-based or usage-based royalties

## Geography

Cardiff Oncology is headquartered in the United States and is listed on Nasdaq Capital Market under CRDF. Its development and regulatory activities are primarily U.S.-based, including clinical work at U.S. institutions such as Dana-Farber Cancer Institute and U.S. patent protection from the USPTO. The company also notes that its business is subject to foreign regulation, which matters because clinical supply, trial operations, and future commercialization may involve non-U.S. jurisdictions. No country-level revenue disclosure was provided in the excerpts, and the company currently has minimal revenue from royalties rather than geographic product sales.

- Headquartered in the United States
- Listed on Nasdaq Capital Market under CRDF
- Clinical trials run mainly through U.S. oncology centers
- U.S. patent protection is important for mCRC claims
- Foreign regulatory exposure exists through drug development and supply chains

## Strategy

The company’s strategy is to validate onvansertib as a differentiated PLK1 inhibitor in biomarker-defined cancer populations, starting with RAS-mutated metastatic colorectal cancer. It is pursuing combination regimens with standard-of-care therapies because that approach can improve the probability of clinical benefit and support a clearer regulatory path. Cardiff Oncology is also broadening evidence generation through investigator-initiated trials in pancreatic cancer, small cell lung cancer, triple negative breast cancer, and CMML to expand the addressable opportunity. Protecting intellectual property, improving patient selection with genomics, and maintaining access to external capital are central to the strategy because the company remains pre-commercial and cash-consuming.

- **Advance lead mCRC program** (short-term) — The lead indication is the clearest path to value creation and potential partnering or approval.
- **Broaden clinical proof-of-concept across tumor types** (medium-term) — Additional data in other cancers can support platform credibility and optionality.
- **Maintain financing runway** (short-term) — The company has substantial doubt about continuing as a going concern without additional capital.

- Advance onvansertib in RAS-mutated metastatic colorectal cancer
- Use combination therapy with standard-of-care drugs to improve efficacy
- Apply biomarker and genomics tools to select responsive patients
- Expand clinical evidence into additional high-unmet-need cancers
- Strengthen patent protection around mCRC combination use
- Preserve cash runway through disciplined R&D and financing access

## Risks

Cardiff Oncology is a clinical-stage company with no approved product revenue, so its business depends on successful trial outcomes, regulatory clearance, and future commercialization of onvansertib. The company explicitly states it has incurred losses since inception, has a substantial accumulated deficit, and faces substantial doubt about its ability to continue as a going concern, which makes financing risk a central issue. Clinical development risk is high because oncology trials are expensive, slow, and uncertain, and competing therapies from much larger companies could reduce the commercial opportunity even if onvansertib shows activity. The company also relies on third-party manufacturers and distributors, so supply disruptions, GMP compliance failures, or raw-material sourcing issues could delay trials and increase costs. As a biotech developer, it also faces regulatory, IP, cybersecurity, and healthcare compliance risks that can materially affect timelines and valuation.

- **Clinical development failure** [critical] — The lead asset is still in development, and efficacy or safety results may not support approval or partnering.
- **Insufficient capital / going concern** [critical] — The company expects its current resources to fund operations only into the first quarter of 2027 and has disclosed substantial doubt about continuing as a going concern.
- **Third-party manufacturing dependence** [high] — The company does not own manufacturing capacity and relies on GMP contract manufacturers for clinical supply.
- **Regulatory approval and compliance** [high] — Drug development is subject to extensive FDA and foreign regulation, and noncompliance can delay or block development.
- **Competition from larger oncology developers** [high] — Better-funded competitors may develop safer, more effective, or cheaper therapies in the same indications.

- Clinical failure risk if onvansertib does not show durable efficacy or safety
- Financing risk because the company is pre-revenue and cash-burning
- Going-concern risk if capital markets access weakens
- Third-party manufacturing dependence can delay clinical supply
- Regulatory approval risk from FDA and other health authorities
- Competition from larger oncology companies with more resources
- Patent and IP risk if claims are challenged or expire earlier than expected
- Cybersecurity and data integrity risk for clinical trial information

## Accounting

The most important accounting issue for Cardiff Oncology is the timing and estimation of research and development expense accruals, especially clinical trial costs that are recognized as services are received but may not yet be invoiced. Because trial activity, patient enrollment, and vendor progress can change quickly, accrual estimates can move materially from quarter to quarter and affect reported operating loss. Revenue is currently minimal and comes from sales-based or usage-based royalties on unrelated intellectual property licenses, so revenue recognition depends on licensee sales activity and timing rather than on product shipments. Investors should also watch stock-based compensation, cash runway disclosures, and any future fair value or impairment judgments as the company continues to operate with limited revenue and external financing needs.

- **Accrued clinical trial expenses** — Quarterly operating loss and balance sheet accruals
- **Usage-based royalty revenue recognition** — Small but variable revenue line
- **Stock-based compensation** — Operating expense and net loss
- **Going-concern assessment** — Investor assessment of solvency and financing risk

- Clinical trial accruals depend on estimates of services received but not yet billed
- R&D expense can fluctuate with patient enrollment and trial progress
- Royalty revenue is usage-based and tied to licensee sales timing
- Stock-based compensation is a meaningful non-cash expense for a small biotech
- Going-concern and liquidity disclosures affect how investors assess financial risk

---

*Last updated: 2026-04-28T14:25:45.393521+00:00*